198 related articles for article (PubMed ID: 31046476)
21. Immunotherapy for urothelial carcinoma: Metastatic disease and beyond.
Poon DM
Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():18-23. PubMed ID: 32852900
[TBL] [Abstract][Full Text] [Related]
22. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
23. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
Teo MY; Rosenberg JE
Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
[TBL] [Abstract][Full Text] [Related]
24. [The role of immunooncology in the treatment of urothelial cancer].
Retz M; Tauber R; Horn T
Aktuelle Urol; 2017 Aug; 48(4):329-335. PubMed ID: 28591872
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.
Yu SS; Ballas LK; Skinner EC; Dorff TB; Sadeghi S; Quinn DI
Clin Adv Hematol Oncol; 2017 Jul; 15(7):543-551. PubMed ID: 28749918
[TBL] [Abstract][Full Text] [Related]
26. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
27. Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma.
Lattanzi M; Balar AV
Curr Oncol Rep; 2019 Feb; 21(3):24. PubMed ID: 30806823
[TBL] [Abstract][Full Text] [Related]
28. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
Milowsky MI; Rumble RB; Booth CM; Gilligan T; Eapen LJ; Hauke RJ; Boumansour P; Lee CT
J Clin Oncol; 2016 Jun; 34(16):1945-52. PubMed ID: 27001593
[TBL] [Abstract][Full Text] [Related]
29. A systematic overview of chemotherapy effects in urothelial bladder cancer.
Nilsson S; Ragnhammar P; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):371-90. PubMed ID: 11441942
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.
Gupta M; Kates M; Bivalacqua TJ
Curr Opin Oncol; 2019 May; 31(3):183-187. PubMed ID: 30893148
[TBL] [Abstract][Full Text] [Related]
31. Current advances in BCG-unresponsive non-muscle invasive bladder cancer.
Tse J; Singla N; Ghandour R; Lotan Y; Margulis V
Expert Opin Investig Drugs; 2019 Sep; 28(9):757-770. PubMed ID: 31412742
[No Abstract] [Full Text] [Related]
32. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
[TBL] [Abstract][Full Text] [Related]
33. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
35. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
36. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy and urothelial carcinoma: An overview and future prospectives.
Pierantoni F; Maruzzo M; Gardi M; Bezzon E; Gardiman MP; Porreca A; Basso U; Zagonel V
Crit Rev Oncol Hematol; 2019 Nov; 143():46-55. PubMed ID: 31476551
[TBL] [Abstract][Full Text] [Related]
38. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer.
Singh A; Osbourne AS; Koshkin VS
Curr Treat Options Oncol; 2023 Sep; 24(9):1213-1230. PubMed ID: 37428331
[TBL] [Abstract][Full Text] [Related]
39. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
Flaig TW
J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
[TBL] [Abstract][Full Text] [Related]
40. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.
Parekh DJ; Bochner BH; Dalbagni G
J Clin Oncol; 2006 Dec; 24(35):5519-27. PubMed ID: 17158537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
